Literature DB >> 28192085

Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Xiaomei Chen1, Richard F Keep2, Yan Liang3, Hao-Jie Zhu4, Margareta Hammarlund-Udenaes5, Yongjun Hu6, David E Smith7.   

Abstract

Peptide transporter 2 (PEPT2) is a high-affinity low-capacity transporter belonging to the proton-coupled oligopeptide transporter family. Although many aspects of PEPT2 structure-function are known, including its localization in choroid plexus and neurons, its regional activity in brain, especially extracellular fluid (ECF), is uncertain. In this study, the pharmacokinetics and regional brain distribution of cefadroxil, a β-lactam antibiotic and PEPT2 substrate, were investigated in wildtype and Pept2 null mice using in vivo intracerebral microdialysis. Cefadroxil was infused intravenously over 4h at 0.15mg/min/kg, and samples obtained from plasma, brain ECF, cerebrospinal fluid (CSF) and brain tissue. A permeability-surface area experiment was also performed in which 0.15mg/min/kg cefadroxil was infused intravenously for 10min, and samples obtained from plasma and brain tissues. Our results showed that PEPT2 ablation significantly increased the brain ECF and CSF levels of cefadroxil (2- to 2.5-fold). In contrast, there were no significant differences between wildtype and Pept2 null mice in the amount of cefadroxil in brain cells. The unbound volume of distribution of cefadroxil in brain was 60% lower in Pept2 null mice indicating an uptake function for PEPT2 in brain cells. Finally, PEPT2 did not affect the influx clearance of cefadroxil, thereby, ruling out differences between the two genotypes in drug entry across the blood-brain barriers. These findings demonstrate, for the first time, the impact of PEPT2 on brain ECF as well as the known role of PEPT2 in removing peptide-like drugs, such as cefadroxil, from the CSF to blood.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood-cerebrospinal fluid barrier; Brain extracellular fluid; Cefadroxil; Microdialysis; Peptide transporter 2

Mesh:

Substances:

Year:  2017        PMID: 28192085      PMCID: PMC5365381          DOI: 10.1016/j.bcp.2017.02.005

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  55 in total

1.  Oral availability of cefadroxil depends on ABCC3 and ABCC4.

Authors:  Dirk R de Waart; Koen van de Wetering; Cindy Kunne; Suzanne Duijst; Coen C Paulusma; Ronald P J Oude Elferink
Journal:  Drug Metab Dispos       Date:  2011-12-13       Impact factor: 3.922

Review 2.  Mammalian peptide transporters as targets for drug delivery.

Authors:  Isabel Rubio-Aliaga; Hannelore Daniel
Journal:  Trends Pharmacol Sci       Date:  2002-09       Impact factor: 14.819

Review 3.  Efflux transport systems for organic anions and cations at the blood-CSF barrier.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Adv Drug Deliv Rev       Date:  2004-10-14       Impact factor: 15.470

Review 4.  Astrocyte-endothelial interactions at the blood-brain barrier.

Authors:  N Joan Abbott; Lars Rönnbäck; Elisabeth Hansson
Journal:  Nat Rev Neurosci       Date:  2006-01       Impact factor: 34.870

5.  Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin.

Authors:  A I Hartstein; K E Patrick; S R Jones; M J Miller; R E Bryant
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

6.  Sucrose and inulin space measurements of cerebral cortex in four mammalian species.

Authors:  V A Levin; J D Fenstermacher; C S Patlak
Journal:  Am J Physiol       Date:  1970-11

7.  δ-Aminolevulinic acid dehydratase single nucleotide polymorphism 2 (ALAD2) and peptide transporter 2*2 haplotype (hPEPT2*2) differently influence neurobehavior in low-level lead exposed children.

Authors:  Christina Sobin; Mayra Gisel Flores-Montoya; Marisela Gutierrez; Natali Parisi; Tanner Schaub
Journal:  Neurotoxicol Teratol       Date:  2014-12-13       Impact factor: 3.763

8.  Enhanced antinociceptive response to intracerebroventricular kyotorphin in Pept2 null mice.

Authors:  Huidi Jiang; Yongjun Hu; Richard F Keep; David E Smith
Journal:  J Neurochem       Date:  2009-04-04       Impact factor: 5.372

9.  Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter.

Authors:  M Boll; M Herget; M Wagener; W M Weber; D Markovich; J Biber; W Clauss; H Murer; H Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications.

Authors:  F Döring; J Walter; J Will; M Föcking; M Boll; S Amasheh; W Clauss; H Daniel
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more
  5 in total

Review 1.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

2.  Evaluation of Blood-CSF Barrier Transport by Quantitative Real Time Fluorescence Microscopy.

Authors:  Austin Sun; Joanne Wang
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.200

3.  Revisiting atenolol as a low passive permeability marker.

Authors:  Xiaomei Chen; Tim Slättengren; Elizabeth C M de Lange; David E Smith; Margareta Hammarlund-Udenaes
Journal:  Fluids Barriers CNS       Date:  2017-10-31

4.  Brain-transportable dipeptides across the blood-brain barrier in mice.

Authors:  Mitsuru Tanaka; Shinya Dohgu; Genki Komabayashi; Hayato Kiyohara; Fuyuko Takata; Yasufumi Kataoka; Takashi Nirasawa; Motohiro Maebuchi; Toshiro Matsui
Journal:  Sci Rep       Date:  2019-04-08       Impact factor: 4.379

5.  Structural snapshots of human PepT1 and PepT2 reveal mechanistic insights into substrate and drug transport across epithelial membranes.

Authors:  Maxime Killer; Jiri Wald; Joanna Pieprzyk; Thomas C Marlovits; Christian Löw
Journal:  Sci Adv       Date:  2021-11-03       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.